The use of D2/D3 dopaminergic agonists in Parkinson's disease (PD) may lead to pathological gambling. In a placebo-controlled double-blind study in healthy volunteers, we observed riskier choices in a lottery task after administration of the D3 receptor-preferring agonist pramipexole thus mimicking risk-taking behavior in PD. Moreover, we demonstrate decreased activation in the rostral basal ga...

Discussion: To date there is a lack of consensus on either the diagnostic criteria of TRBD or evidence-based guidelines for the treatment of TRBD. Adjunctive modafinil, pramipexole, tranylcypromine and vagus nerve stimulation have been tried but the response rate is variable. Family-focused treatment, group psychoeducation and interpersonal and social rhythm therapy have been tried in bipolar d...

Parkinson's disease, a neurodegenerative disorder characterized by movement abnormalities, is frequently complicated by psychiatric syndromes. Psychiatric symptoms may be the direct result of PD, its co-morbid pathologies, or occur as a side effect of its pharmacotherapy. Pramipexole, like other dopamine agonists for treating Parkinson's disease , has a tendency to induce psychotic and manic sy...

BACKGROUND The neuroanatomic substrate of restless legs syndrome (RLS) is poorly understood, and the diagnosis is clinically made based upon subjective sensory symptoms, although a motor component is usually present. CASE REPORT We report two cases of elderly patients with spinal pathology who were referred by neurologists for myoclonus. Both had semi-rhythmic leg movements that partially imp...

Apomorphine and certain ergot alkaloids (bromocriptine, lisuride and pergolide) have been available for several decades; for the last few years, they were joined by newer dopamine agonists (cabergoline, pramipexole and ropinirole) most of them are non-ergolines. Each of these dopamine agonists has its own pharmacological characteristics and occupies a place in the pharmacotherapy of Parkinsons ...

D a t a e x t r a c t i o n Studies were rated for quality (class I [highquality randomized controlled trials with blinded outcome assessment] to class IV [uncontrolled studies, case series, case reports, or expert opinion]). M a i n r e s u l t s Selegiline: 2 class-II studies on the neuroprotective effects of selegiline were included. Selegiline improved symptoms, but the evidence was insuffi...